Search
for
Sort by
Research 121–150 of 1000+
- Dermatological drugs and cosmetics
- Safety of a Perfluorodecalin-Infused Silicone Patch in Picosecond Laser-Assisted Tattoo Removal
- A multicentre trial of the epilation efficacy of a new, large spot size, constant spectrum emission IPL device
- Efficacy of Ginger Supplementation in Relieving Persistent Hypothyroid Symptoms in Patients with Controlled Primary Hypothyroidism: A Pilot Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Effect of COVID-19 on Hair Diseases Observed by Health Care Providers: Analysis of 513 participants
- Efficacy, Safety, and Tolerability of a Triple Wavelength Laser for Hair Reduction in Indian Women: A Prospective Clinical Study
- Co-existence of Systemic Lupus Erythematosus and Celiac Disease: A Case Report
- How We Do It
- Evidence-based approach to cutaneous hyperandrogenism in women
- Frontal Fibrosing Alopecia: Successfully Treated with Methotrexate or Just the Natural Disease Progression?
- Scoring systems for pemphigus
- Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Real-World Assessment of Disease Characteristics and Clinical Outcomes in Alopecia Areata in a Global Noninterventional Observational Cohort (ADAAGIO)
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
- Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
- Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Revolutionizing psoriasis care: Microneedle innovations in treatment and diagnosis
- Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
- Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Ecological dynamics of <em>Malassezia</em> in the hair follicle homeostasis, dysbiosis, and disease
- Factors associated with risk for depression among women with polycystic ovarian syndrome